TABLE 2.
Antitumor activity of the study treatment
| Efficacy variables | Number of patients [cases (%)] |
|---|---|
| Best overall response | |
| Complete response | 1 (4.3) |
| Partial response | 11 (47.8) |
| Stable disease | 5 (21.7) |
| Progressive disease | 5 (21.7) |
| Unconfirmed partial response a | 1 (4.3) |
| Objective response | 12 (52.2) |
| Disease control | 17 (73.9) |
| Median progression‐free survival | 8.5 months (95% CI:1.2–15.8) |
| Median overall survival | 11.6 months (95% CI:6.7–16.6) |
a
One patient at follow‐up after study treatment discontinuation due to consent withdrawal achieved an unconfirmed partial response prior to receiving any additional anticancer treatments.